Bruera, G., Cannita, K., Di Giacomo, D., Lamy, A., Troncone, G., Dal Mas, A., . . . Ricevuto, E. (2012). Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease. BioMed Central.
Chicago Style CitationBruera, Gemma, et al. Prognostic Value of KRAS Genotype in Metastatic Colorectal Cancer (MCRC) Patients Treated With Intensive Triplet Chemotherapy Plus Bevacizumab (FIr-B/FOx) According to Extension of Metastatic Disease. BioMed Central, 2012.
MLA CitationBruera, Gemma, et al. Prognostic Value of KRAS Genotype in Metastatic Colorectal Cancer (MCRC) Patients Treated With Intensive Triplet Chemotherapy Plus Bevacizumab (FIr-B/FOx) According to Extension of Metastatic Disease. BioMed Central, 2012.